November 2024 in “Journal of Investigative Dermatology” Serotonin helps wounds heal faster.
September 2017 in “Journal of Investigative Dermatology” LRIG1 protein affects hair growth by regulating skin receptors, leading to hair loss when overexpressed.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
1 citations
,
January 2018 in “Journal of Neurology Research” A young man had rare serious side effects from an epilepsy drug, leading to stopping the drug.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
9 citations
,
January 2024 in “International Journal of Dermatology”
148 citations
,
April 2009 in “Molecular Pharmaceutics” Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
1 citations
,
April 2012 in “Informa Healthcare eBooks” Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
2 citations
,
November 2017 in “Elsevier eBooks” Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
January 2024 in “Current research in toxicology” Thallium is highly toxic, causing severe health issues, and Prussian blue is the best antidote.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
119 citations
,
October 1992 in “Fundamental & Clinical Pharmacology” Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.
1 citations
,
January 2025 in “Proceedings of the National Academy of Sciences” LPAR6 has a unique way of binding and activating, which helps in designing treatments for hair loss and cancer.
March 2026 in “Folia Histochemica et Cytobiologica” LTBP1 is a key regulator in diseases and a potential target for new treatments.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
130 citations
,
November 2017 in “Frontiers in Immunology” The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
2 citations
,
June 2023 in “Journal of cell science” Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
May 2012 in “CRC Press eBooks” Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
April 2023 in “Journal of Investigative Dermatology” RNase L suppresses regeneration in mammals.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.